These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21111693)

  • 1. Management of chronic hepatitis C in childhood: the impact of therapy in the clinical practice during the first 2 decades.
    Bortolotti F; Indolfi G; Zancan L; Giacchino R; Verucchi G; Cammà C; Barbera C; Resti M; Marazzi MG; Guido M
    Dig Liver Dis; 2011 Apr; 43(4):325-9. PubMed ID: 21111693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1.
    Tsang OT; Zee JS; Chan JM; Li RS; Kan YM; Li FT; Lo FH; Chow DA; Cheung KW; Chan KH; Yeung YW; Ng FH; Li MK; Kwan WK; Lai TS
    J Gastroenterol Hepatol; 2010 Apr; 25(4):766-71. PubMed ID: 20492332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peginterferon and ribavirin for chronic hepatitis C.
    Hoofnagle JH; Seeff LB
    N Engl J Med; 2006 Dec; 355(23):2444-51. PubMed ID: 17151366
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of peginterferon α-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: an open-label study in central and Eastern Europe.
    Husa P; Oltman M; Ivanovski L; Rehák V; Messinger D; Tietz A; Urbanek P
    Eur J Gastroenterol Hepatol; 2011 May; 23(5):375-81. PubMed ID: 21502923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis.
    Kim SR; Imoto S; Mita K; Taniguchi M; Sasase N; Muramatsu A; Kudo M; Kitai S; El-Shamy A; Hotta H; Hayashi Y
    Digestion; 2009; 79(1):36-9. PubMed ID: 19246919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
    N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world outcomes in patients with chronic hepatitis C: primary results of the PROBE study.
    Craxì A; Piccinino F; Ciancio A; Iannacone C; Deodato B; Golotta C; Ascione A
    Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):388-95. PubMed ID: 24569819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegylated IFN-α-2a and ribavirin in the treatment of hepatitis C infection in children.
    Pawlowska M
    Expert Opin Drug Saf; 2015 Mar; 14(3):343-8. PubMed ID: 25599750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High sustained virological response rate to combination therapy in genotype 1 patients with histologically mild hepatitis C.
    Gheorghe L; Iacob S; Grigorescu M; Sporea I; Sirli R; Damian D; Gheorghe C; Iacob R
    J Gastrointestin Liver Dis; 2009 Mar; 18(1):51-6. PubMed ID: 19337634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter study on the discontinuation and efficacy of chronic hepatitis C treatment in the Spanish penitentiary population (EPIBAND study).
    Juan Jd; de la Hoya PS; Marco A; Antón JJ; Faraco I; Yllobre C; Pozo E; Hoyos C
    Eur J Gastroenterol Hepatol; 2014 Oct; 26(10):1083-9. PubMed ID: 25076064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to pegylated interferon alpha-2b and ribavirin in children with chronic hepatitis C.
    Baker RD; Dee D; Baker SS
    J Clin Gastroenterol; 2007 Jan; 41(1):111-4. PubMed ID: 17198073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus therapy to date.
    Foster G; Mathurin P
    Antivir Ther; 2008; 13 Suppl 1():3-8. PubMed ID: 18432157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
    Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
    Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment for chronic hepatitis C in children: a review.
    Palumbo E
    Am J Ther; 2009; 16(5):446-50. PubMed ID: 19262360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
    Pessôa MG; Cheinquer H; Almeida PR; Silva GF; Lima MP; Paraná R; Lacerda MA; Parise ER; Pernambuco JR; Pedrosa SS; Teixeira R; Sette H; Tatsch F
    Ann Hepatol; 2012; 11(1):52-61. PubMed ID: 22166561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks.
    Sarrazin C; Schwendy S; Möller B; Dikopoulos N; Buggisch P; Encke J; Teuber G; Goeser T; Thimme R; Klinker H; Boecher WO; Schulte-Frohlinde E; Prinzing R; Herrmann E; Zeuzem S; Berg T
    Gastroenterology; 2011 Nov; 141(5):1656-64. PubMed ID: 21784046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary study of two antiviral agents for hepatitis C genotype 1.
    Lok AS; Gardiner DF; Lawitz E; Martorell C; Everson GT; Ghalib R; Reindollar R; Rustgi V; McPhee F; Wind-Rotolo M; Persson A; Zhu K; Dimitrova DI; Eley T; Guo T; Grasela DM; Pasquinelli C
    N Engl J Med; 2012 Jan; 366(3):216-24. PubMed ID: 22256805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.